SCHEMBL5197342

SCHEMBL5197342

Cc1ccc(-c2ccc3cc(-c4c(C5CCCCC5)c5ccc(C(=O)O)cc5n4CC(=O)N4CCOCC4)ccc3n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HSD17B10 Q99714 2/20 0.41
TP53 P04637 2/20 0.41
USP2 O75604 1/20 0.41
POLB P06746 1/20 0.41
TSHR P16473 1/20 0.41
GRIN2B Q13224 3/20 0.38
BRD4 O60885 2/20 0.37
CREBBP Q92793 1/20 0.37
SCN9A Q15858 1/20 0.37
GAA P10253 2/20 0.37
PRKCA P17252 1/20 0.36
MMP12 P39900 1/20 0.36
EGLN1 Q9GZT9 1/20 0.36
EGFR P00533 1/20 0.36
TYMS P04818 1/20 0.36
LTA4H P09960 1/20 0.36
VDR P11473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5197401 0.94 ALDH1A1 (0.39) HPGDKDM4EALDH1A1HSD17B10TP53
SCHEMBL5197877 0.93 GRIN2B (0.42) HPGDKDM4EALDH1A1HSD17B10TP53
SCHEMBL5197025 0.93 BRD4 (0.36) KDM4EALDH1A1TP53GRIN2BBRD4
SCHEMBL5197220 0.93 HRH1 (0.41) HPGDALDH1A1GRIN2BSCN9APRKCA
SCHEMBL5219759 0.93 TMEM97 (0.37) HPGDALDH1A1POLBTSHRBRD4
SCHEMBL5198279 0.92 L3MBTL1 (0.44) HPGDKDM4EALDH1A1HSD17B10TP53
SCHEMBL5197163 0.92 SCN9A (0.37) HPGDKDM4EALDH1A1HSD17B10TP53
SCHEMBL5197829 0.92 BRD4 (0.36) HPGDKDM4EALDH1A1HSD17B10TP53
SCHEMBL5222201 0.91 MOK (0.44) HPGDALDH1A1POLBSCN9A
SCHEMBL5197055 0.91 P2RY14 (0.39) HPGDTP53USP2GRIN2BSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1844042-A1 INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2007-10-17 EP claimed
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses GENELABS, INC. 2006-09-21 US claimed
WO-2006076529-A1 INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2006-07-20 WO claimed
EP-1844042-A1 INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2007-10-17 EP disclosed
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses GENELABS, INC. 2006-09-21 US disclosed
WO-2006076529-A1 INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses HAVCR2, ZC3HAV1, SARS1 HPGD 2684/4885KDM4E 2663/4885ALDH1A1 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.